Muscular Dystrophy: CepTor Receives $12 Million for R&D

CepTor is a biopharmaceutical company focused on the development of cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases. The company is focusing its efforts on its lead product, MYODUR, for Duchenne's muscular dystrophy (MD). Currently, there is no cure for this disease that affects between 50,000-250,000 sufferers annually. In addition, CepTor is developing products for multiple sclerosis and epilepsy.
Medical News Today